AbCellera Biologics Inc.
ABCL · XNASCIK 1703057fmd_1P4DCCNCDQSXTNWQ0E6SHCDBC2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 12 | 233 | 375 | 485 | 38 | 29 | 75 |
| Research and development | 10 | 29 | 62 | 108 | 176 | 167 | 187 |
| Selling, general and administrative | 4 | 16 | 49 | 67 | 75 | 85 | – |
| Total operating expenses | 16 | 77 | 171 | 269 | 275 | 344 | 292 |
| Operating income | (4) | 156 | 204 | 217 | (237) | (315) | (217) |
| Interest and investment income | 0 | 0 | 3 | 16 | 42 | 38 | 28 |
| Other non-operating income (expense) | 2 | 2 | 15 | 23 | 63 | 114 | 40 |
| Income before taxes | (2) | 158 | 219 | 239 | (174) | (200) | (178) |
| Income tax expense | – | 39 | 66 | 81 | (28) | (38) | (31) |
| Net income from continuing operations | – | 119 | 153 | 159 | (146) | (163) | (146) |
| Net income | (2) | 119 | 153 | 159 | (146) | (163) | (146) |
| Net income to common shareholders | (2) | 85 | 153 | 159 | (146) | (163) | (146) |